Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial

(RTTNews) - Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomi https://www.nasdaq.com/articles/compugen-to-receive-$10-mln-payment-after-dosing-first-patient-in-astrazenecas-artemide